Expert commercial strategy and business planning, acquisition/licensing opportunity evaluation and BD support, modeling/forecasting and valuation, and market research for Life Sciences - working with
pharma, biotech, medtech, startups, and investors
Key Services & Capabilities
Combining expert analytical acumen with in-depth market experience
Opportunity Assessment and Commercial Due Diligence
Maximize insight for evaluating and prioritizing potential targets or presenting to potential partners
Opportunity screening and sourcing: asset-, therapeutic area-, and technology-based
Target prioritization frameworks and execution
Competitive intelligence and pipeline assessment
Commercial due diligence and comprehensive business case development
C-suite and investor presentations, briefs,
and pitch decks
Modeling and Forecasting
Customized approaches for
unconventional market challenges
Utilization and revenue models: clinical/ epidemiological-, volume-based
market-tracking and portfolio models
Medical device and technology models - including CapEx+consumable spend, services/ support/ licenses, pull-through dynamics
Company and portfolio valuation modeling (NPV/IRR/NAV)
Commercial reporting, P&L, and long-term planning
and Business Planning
Help differentiate and shepherd products
to reach their potential
Product positioning and differentiation
New product commercial strategy and development
Portfolio strategy and optimization
Business plan development and gap analysis
Launch planning and market entry strategy
Leveraging deep expertise in rare/orphan disease and specialty products
Market Insights and Analytics
Expert analytical acumen to
optimally inform business decisions
Market research - primary and secondary, qualitative and quantitative
- Product profile development, testing, and refinement
- Engaging diverse stakeholders - thought leaders, clinicians/HCPs, advocates, and patients
- Product and market performance analysis
- Sales force planning, targeting, and profiling
Top Global Pharma
Project types: Rare Disease Chart Review & Commercial Strategy / Vaccine Opportunity Assessment / Positioning & Messaging
Shlomo Harnas is a seasoned commercial strategist and BD/M&A/licensing evaluation professional with extensive experience in biopharma, medtech, and healthcare across consulting and industry. His work encompasses opportunity assessments and due diligence, valuations and deal support, developing and refining business cases, new product and portfolio strategy/prioritization, and commercial and market entry strategy in the US, EU, and emerging markets (BRIC, Latin America).
He is the Managing Director of Akrolyth Advisory, working on both buy-side and sell-side with industry, VC and PE investors, and translational research groups. He was previously the North America Commercial Director for Grünenthal, a Germany-based global pharma, where he was responsible for commercial development and BD evaluation/assessments, and was Commercial lead for a mid-late stage rare disease program.
Prior to that, he was the go-to diligence/LM&A lead with Navigant Consulting’s global Life Science practice, as well as a member of Leerink Swann’s advisory group and of Clarion Healthcare’s strategy practice. Shlomo also works with startups and accelerators as a mentor, advisor, and investor.
Throughout his career, Shlomo has been especially valued for his depth of insight, versatility and speed in gaining mastery of new subjects, and ability to navigate complexity and provide structure and clarity to challenging questions.
Shlomo holds a Master’s degree in Biology from the Massachusetts Institute of Technology, where he was a Presidential Doctoral Fellow, and a Master’s/Bachelor’s in Biochemistry and Mathematics from Brandeis University, summa cum laude, with highest honors, where he was a Goldwater Scholar and Howard Hughes Medical Institute fellow.
He has lived in 4 countries, is fluent in English and Portuguese, and is conversant in 3 more languages.